Apnimed, Inc. (Nasdaq: APMD) released its financial results for the third quarter ended September 30, 2026, and provided an update on its lead drug candidate, AD109 (proposed proprietary name Oxnimbi). The company reported a net loss of $29.5 million for the quarter, compared to a net loss of $10.9 million in the prior year period. This increase was driven by higher research and development expenses, which rose to $11.8 million from $9.8 million, and general and administrative expenses, which surged to $22.6 million from $6.0 million. The rise in G&A expenses was attributed to professional services, infrastructure costs for commercial readiness, and increased stock-based compensation.

Despite the operating losses, Apnimed reported a strong cash position. As of September 30, 2026, the company held $351.8 million in cash and cash equivalents. This figure includes approximately $198.9 million in net proceeds from an upsized initial public offering completed in August 2026. The company stated that this cash balance is expected to fund operations and the potential U.S. launch of Oxnimbi through the second quarter of 2028.

The primary focus of the filing is the regulatory status of AD109. The New Drug Application (NDA) for AD109, a combination of aroxybutynin and atomoxetine designed to treat obstructive sleep apnea (OSA), remains under review by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027. Apnimed noted that commercial readiness activities, including market access and payer engagement, are advancing in preparation for a potential launch subject to FDA approval.

In addition to the financial and regulatory updates, Apnimed highlighted its clinical presentation at the CHEST 2026 Annual Meeting. The company presented five abstracts, including two late-breakers, featuring Phase 3 AD109 data and real-world studies on the burden of OSA. The company emphasized that AD109 is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse.